Aarhus, Denmark (UroToday.com) Joep J. de Jong from the Erasmus MC Cancer Institute in Rotterdam discussed efforts at developing a genomic classifier to predict clinically aggressive luminal bladder tumors. 

Using TURBT specimens from 206 patients with high-grade cT1-T2 N0M0 bladder cancer who subsequently underwent radical cystectomy without neoadjuvant chemotherapy, patients who were found to be upstaged at the time of RC with a luminal subtype were identified. A luminal upstaging classifier was then developed based on microarray expression data (n=75). This was then tested on a separate cohort of luminal tumors from the same sample set (not used in the training model) and found to predict upstaging in 32/34 cases. Although this classifier remains unvalidated to date, it holds promise potentially in helping identify which patients with luminal bladder cancer may benefit from upfront neoadjuvant chemotherapy.
IBCN Conclusions

Presented by: Joep J. de Jong, Department of Urology, Erasmus MC Cancer Institute in Rotterdam, Netherlands

Written by Dr. Vikram M. Narayan (@VikramNarayan), Urologic Oncology Fellow with Ashish M. Kamat, MD (@UroDocAsh), Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 17th meeting of the International Bladder Cancer Network, (IBCN, #IBCN2019) October 3rd – 5th, 2019 in Aarhus, Denmark.